Zacks: Analysts Anticipate Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to Post $0.61 EPS

Wall Street brokerages forecast that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will post earnings of $0.61 per share for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Teva Pharmaceutical Industries’ earnings, with the lowest EPS estimate coming in at $0.56 and the highest estimate coming in at $0.67. Teva Pharmaceutical Industries reported earnings of $0.53 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 15.1%. The firm is expected to report its next earnings results on Wednesday, February 12th.

On average, analysts expect that Teva Pharmaceutical Industries will report full-year earnings of $2.38 per share for the current year, with EPS estimates ranging from $2.25 to $2.48. For the next year, analysts anticipate that the company will post earnings of $2.52 per share, with EPS estimates ranging from $2.36 to $2.76. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.02. The business had revenue of $4.34 billion during the quarter, compared to the consensus estimate of $4.25 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.04% and a negative net margin of 21.94%. The business’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.78 EPS.

TEVA has been the subject of a number of recent research reports. Wolfe Research initiated coverage on Teva Pharmaceutical Industries in a research note on Friday, July 19th. They set a “peer perform” rating and a $9.00 price target for the company. Wells Fargo & Co cut their price objective on Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating for the company in a research note on Monday, September 30th. Morgan Stanley downgraded Teva Pharmaceutical Industries from an “equal weight” rating to an “underweight” rating and cut their price objective for the company from $16.00 to $6.00 in a research note on Monday, July 15th. Guggenheim began coverage on Teva Pharmaceutical Industries in a research note on Thursday, September 12th. They set a “neutral” rating for the company. Finally, UBS Group set a $8.00 price objective on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Friday, August 16th. Six analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $10.78.

Several large investors have recently made changes to their positions in the stock. AdvisorNet Financial Inc lifted its holdings in Teva Pharmaceutical Industries by 71.3% in the 3rd quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock worth $25,000 after purchasing an additional 1,525 shares in the last quarter. First Interstate Bank purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $28,000. Motco purchased a new position in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $28,000. Lindbrook Capital LLC lifted its holdings in Teva Pharmaceutical Industries by 76.6% in the 3rd quarter. Lindbrook Capital LLC now owns 4,461 shares of the company’s stock worth $31,000 after purchasing an additional 1,935 shares in the last quarter. Finally, Pacer Advisors Inc. purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $32,000. Institutional investors own 58.21% of the company’s stock.

Shares of Teva Pharmaceutical Industries stock traded up $0.83 during trading hours on Tuesday, reaching $9.30. 34,192,717 shares of the stock traded hands, compared to its average volume of 16,922,125. The company has a 50 day moving average price of $7.51 and a 200 day moving average price of $8.90. The firm has a market capitalization of $9.32 billion, a price-to-earnings ratio of 3.32, a P/E/G ratio of 0.89 and a beta of 1.73. Teva Pharmaceutical Industries has a one year low of $6.07 and a one year high of $23.97. The company has a quick ratio of 0.62, a current ratio of 0.96 and a debt-to-equity ratio of 1.73.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: Which market index is the best?

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.